Jubilant Life Sciences receives ANDA approval for Rosuvastatin calcium tablets

Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval for Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg, and 40 mg, the generic version of Crestor of IPR Pharmaceuticals, which is used for the treatment of hyperlipidemia or mixed dyslipidemia.

November 01, 2016 / 15:31 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated November 01, 2016, titled "Jubilant Life Sciences receives ANDA approval for Rosuvastatin Calcium Tablets".Source : BSE

Read all announcements in Jubilant Life

first published: Nov 1, 2016 03:31 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347